Medicine Information

Dasacent

Name: Dasacent
Brand: Dasacent
Rating: 4.5 (117 reviews)

Tablet50 mgAntineoplastic agent, Kinase inhibitorATC: L01XE06

Generic Name

Dasatinib

Manufacturer

Example Pharma Ltd.

Country

Bangladesh

Loading images...

Price Details

Current market pricing information

Variant	Unit Price	Strip Price
dasacent 50 mg tablet	৳ 200.00	৳ 2,000.00

Description

Overview of the medicine

Dasacent 50 mg Tablet contains Dasatinib, an antineoplastic agent used to treat certain types of leukemia. It works by blocking specific enzymes (tyrosine kinases) involved in cancer cell growth.

Uses & Indications

Treatment of newly diagnosed adults with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase.

Treatment of adults with chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib.

Treatment of adults with Ph+ acute lymphoblastic leukemia (ALL) with resistance or intolerance to prior therapy.

Treatment of pediatric patients with newly diagnosed Ph+ CML in chronic phase or Ph+ ALL.

Dosage

Adults

Ph+ CML (chronic phase): 100 mg once daily. Ph+ CML (accelerated/myeloid/lymphoid blast phase) or Ph+ ALL: 140 mg once daily. Doses can be adjusted based on response and toxicity.

Elderly

No specific dosage adjustment recommended based solely on age, but close monitoring for adverse effects is advised.

Renal_impairment

No specific dosage adjustment recommended for mild to moderate renal impairment. Use with caution in severe renal impairment (CrCl <30 mL/min).

How to Take

Take orally once daily, with or without food. Swallow the tablet whole; do not crush, cut, or chew. Avoid handling crushed or broken tablets.

Mechanism of Action

Dasatinib is a small molecule tyrosine kinase inhibitor that targets multiple tyrosine kinases, including BCR-ABL, SRC family kinases (SRC, LCK, YES, FYN), c-KIT, EPHA2, and PDGFRβ. By inhibiting these kinases, it prevents the phosphorylation of proteins involved in cell proliferation, survival, and differentiation, leading to apoptosis of cancer cells.

Pharmacokinetics

Onset

Not precisely defined, but anti-leukemic effects can be observed within weeks.

Excretion

Mainly excreted in feces (85%) after hepatic metabolism, with minor renal excretion (4%).

Half life

Approximately 3-5 hours.

Absorption

Rapidly absorbed, peak plasma concentrations typically occur within 0.5 to 6 hours. Absolute bioavailability is unknown but variable. Food can increase or decrease absorption depending on the formulation and gastric pH.

Metabolism

Extensively metabolized, primarily by CYP3A4. Main metabolites are hydroxylated derivatives.

Side Effects

Contraindications

Hypersensitivity to dasatinib or any component of the formulation.
Pregnancy (due to potential for fetal harm).

Drug Interactions

Strong CYP3A4 Inducers (e.g., Rifampin, Phenytoin, Carbamazepine, Phenobarbital, St. John's wort)

May significantly decrease dasatinib plasma concentrations, reducing efficacy. Avoid coadministration.

H2 Blockers (e.g., Famotidine, Ranitidine) & Proton Pump Inhibitors (PPIs) (e.g., Omeprazole, Esomeprazole)

May reduce dasatinib absorption due to increased gastric pH. Antacids may be considered as an alternative (separated by 2 hours). Avoid H2 blockers and PPIs.

Strong CYP3A4 Inhibitors (e.g., Ketoconazole, Itraconazole, Clarithromycin, Telithromycin, Ritonavir, Atazanavir, Indinavir, Nelfinavir, Saquinavir, Grapefruit juice)

May significantly increase dasatinib plasma concentrations, increasing toxicity. Avoid coadministration or reduce dasatinib dose if unavoidable.

Storage

Store below 30°C in a dry place, away from light and moisture. Keep out of reach of children.

Overdose

Experience with overdose is limited. In cases of overdose, patients should be closely observed for signs and symptoms of adverse reactions. General supportive measures should be implemented.

Pregnancy & Lactation

Dasatinib can cause fetal harm when administered to a pregnant woman. Advise pregnant women of the potential risk to the fetus. Women of childbearing potential should be advised to avoid becoming pregnant while taking dasatinib. It is not known whether dasatinib is excreted in human milk. Due to potential for serious adverse reactions in breastfed infants, advise women not to breastfeed during treatment.

Frequently Asked Questions

Common questions about this medicine

Pack Sizes

10 tablets per pack30 tablets per pack

Shelf Life

Typically 24-36 months from manufacturing date, check specific packaging.

Availability

Pharmacies, hospitals

Approval Status

Approved by FDA and other regulatory bodies

Patent Status

Patent expired/expiring for original compound, generics available

Clinical Trials

Dasatinib has been studied in numerous clinical trials, including the DASISION (Dasatinib versus Imatinib Study in Treatment-Naïve CML Patients) trial for newly diagnosed CML and various studies for imatinib-resistant or intolerant CML/ALL. These trials established its efficacy and safety profile.

Lab Monitoring

Complete blood counts (CBC) with differential should be performed weekly for the first 2 months and then monthly, or as clinically indicated.
Liver function tests (LFTs) should be monitored regularly.
Serum electrolytes should be monitored, especially for hypokalemia or hypomagnesemia.
Cardiac function (ECG, echocardiogram) should be assessed periodically, especially in patients with cardiac risk factors.

Doctor Notes

Monitor CBC weekly for the first 2 months, then monthly. Adjust dose for grade 3/4 myelosuppression.
Assess for fluid retention, especially pleural effusions. May require diuretics or dose modification.
Counsel patients on potential drug interactions, especially with CYP3A4 inhibitors/inducers and acid-reducing agents.
Consider baseline ECG and regular monitoring for QTc prolongation.

Patient Guidelines

Take Dasacent exactly as prescribed by your doctor.
Report any unusual bleeding, bruising, fever, or signs of infection immediately.
Inform your doctor about all other medications, herbal products, and supplements you are taking.
Avoid grapefruit products while on this medication.

Missed Dose Advice

If a dose is missed, do not take an additional dose. Take the next scheduled dose at your regular time. Do not take two doses at the same time to make up for a missed dose.